Case Report

Surgical management of giant cell tumor invading the occipital bone: A case report and literature review

Jhon E. Bocanegra-Becerra1, Marco Gonzales-Portillo Showing2,3, Luis A. Huamán Tanta2,3

1School of Medicine, Universidad Peruana Cayetano Heredia, 2Department of Neurosurgery, Instituto de Neurociencias de Lima, 3Clínica San Felipe, Lima, Perú.

E-mail: Jhon E. Bocanegra-Becerra - jhon.bocanegra.b@upch.pe; *Marco Gonzales-Portillo Showing - marcogps@outlook.com; Luis A. Huamán Tanta - ladrianht@yahoo.es

INTRODUCTION

Giant cell tumor of bone (GCTB), also known as “osteoclastoma,” represents 3–5% of primary bone tumors and 10–20% of those of benign origin.[2,27] It commonly originates from the epiphysis of long bones, where it destroys the bony tissue. The skull is a rare presentation site and accounts for <1% of cases.[11,12] Particularly, few cases have been reported in the occipital bone compared to the temporal, frontal, sphenoid, and ethmoidal bones. [4-7,13,15-17,19,21-23,26,28-31,33,37,43,45,47-49,51,53-55] Weng et al. reported that the overall distribution of cases in the occipital bone was 9.8%. [51] This tumor is more common among adults, and gender distribution has been previously reported to be more common in females.[27] However, a systematic review revealed that it might be equal among adults.[12]

The risk factors for the origin of GCTB in the skull base or vault are still unknown. [2,27,46,51] From an embryological point of view, GCTB was thought to originate from bones in the skull base...
formed by endochondral ossification, such as the sphenoid and temporal bones.[5,20,53] Nevertheless, cases in cranial vault bones that form by intramembranous ossification have challenged the initial paradigm.[24,25] As exemplified in our case, the tumor originated in the occipital bone.

Despite the benign nature of this tumor, its clinical behavior may be unpredictable, and the treatment is highly dependent on location, especially in the skull.[51] Furthermore, the recurrence rate can reach up to 30%.[12,15,51] The causes of recurrence after surgical resection are unclear, and the clinical outcomes differ with treatment modalities used in GCTB of long bones.[12]

We conducted a review of the literature, which yielded 27 reported cases of GCTB originating in the occipital bone (retrieval of full-text information, including patient sex and age, type of treatment, and presence of recurrence during the follow-up was possible in 22 cases, and is shown in Table 1).[1,4,7,15-17,21-23,28-31,33,43,45,47-49,51,54,55] To the best of our knowledge, this is the first case of a GCTB of the occipital bone in a Hispanic patient. Besides, our review constitutes the most comprehensive compilation of cases in the occipital region.

### Table 1: Case reports of giant cell tumor of the occipital bone.

| S. No. | Author (year)         | Age* | Sex | Treatment                  | Follow-up period and presence of recurrence |
|--------|-----------------------|------|-----|----------------------------|---------------------------------------------|
| 1.     | Troell et al. (1930)  | 20   | M   | STR                        | 3 years                                    |
| 2.     | Moyes (1970)          | 13   | F   | STR+2650 rads in 12 days   | 9 months                                   |
| 3.     | Arseni (1975)         | 8    | F   | GTR                        | 7 years                                    |
| 4.     | Motomochi et al. (1985) | 53   | M   | Partial resection+2400 rads | 2 years                                    |
| 5.     | Henderson and Whitwell (1988) | 16   | F   | GTR                        | 1.3 years                                  |
| 6.     | Sharma and Newton (1991) | 12   | M   | GTR                        | 2 weeks                                    |
| 7.     | Bertoni et al. (1992) | 58   | F   | STR+RT                     | 12 months: death                           |
| 8.     | Opitz et al. (1996)   | 24   | M   | STR                        | 7 years                                    |
| 9.     | Harris et al. (2004)  | 24   | F   | GTR                        | 10 years                                   |
| 10.    | Young-Min et al. (2004) | 25   | F   | GTR                        | NR                                         |
| 11.    | Modkovski et al. (2009) | 27   | F   | GTR                        | Yes                                        |
| 12.    | Sung et al. (2010)    | 7    | M   | GTR                        | 16 months                                  |
| 13.    | Lu et al. (2011)      | 19   | F   | GTR                        | NR                                         |
| 14.    | Zhang et al. (2013)   | 19   | F   | GTR                        | 1 year                                     |
| 15.    | Usho et al. (2014)    | 22   | F   | STR+50 Gy by external RT+200 cGy/fraction | 31 months                                  |
| 16.    | Kalani et al. (2017)  | 73   | F   | GTR                        | 20 months                                  |
| 17.    | Töret et al. (2019)   | 10 days | M | GTR                        | 5 months                                   |
|        |                       |      |     | Cisplatin 1 mg/kg/day (1–3 days) and doxorubicin 1 mg/ kg/day (1,2 days) 4 times monthly | 60 months                                  |
| 18.    | Kajiwara et al. (2019) | 56   | M   | STR+Denosumab               | 5 years                                    |
| 19.    | Kadipasaoglu et al. (2021) | 9    | F   | GTR                        | 0.5 years                                  |
| 20.    | Chugh et al. (2022)   | 13   | M   | GTR                        | 6 months                                   |
| 21.    | Present Case (2022)   | 40   | F   | GTR                        | 10 months                                  |

F: Female, GTR: Gross total resection, M: Male, NR: Not reported, RT: Radiotherapy, STR: Subtotal resection, *Reported in years except in one patient.

### CASE REPORT

A 40-year-old Hispanic woman presented to the clinic with a 3-month history of neck pain and a bulging lesion on the retromastoid area. The patient had no significant medical history. The physical examination showed a tender and swollen area on the right lateral side of the occipital bone, behind the mastoid process. Besides, the neurologic examination was intact without motor, visual, or sensory deficits.

A brain magnetic resonance imaging (MRI) was obtained. The T1-weighted image with gadolinium showed an extradural and contrast-enhancing lesion destroying the inner and outer layers of the right occipital bone, which extended into the scalp and posterior fossa. It measured 42.5 × 33.5 × 39 mm. The T2-weighted image and the fluid-attenuated inversion recovery (FLAIR) sequence demonstrated a hypointense lesion with multiple thin septa, fluid-fluid levels, and signs of a hemorrhagic component [Figure 1].

### Surgical management

The patient was placed in a three-quarter prone position with flexion of the neck and slight head rotation. Then, a
suboccipital craniotomy was performed with complete gross total resection (GTR) of the lesion. On lifting the scalp, an irregular, rounded, and brownish lesion was exposed at the surface of the right occipital bone [Figures 2 and 3a]. Besides, a deep part of the tumor invading the posterior fossa was resected [Figure 3b]. Surgery was completed without intraoperative complications. Postoperatively, the patient neurologic examination was normal. An MRI was obtained and showed complete resection of the tumor [Figure 4].

Histopathological findings

The histopathological examination of the tumor revealed fusocellular proliferation with fibrohistiocytic characteristics and hemorrhagic changes, zones of hemosiderin, and significant proliferation of scattered osteoclast-type giant multinucleated cells [Figure 5]. These findings suggested the diagnosis of a giant cell tumor of the occipital bone.

Follow-up

The patient has been followed up for 10 months, and she has not developed any neurological deficits or impairment of life functioning. In addition, a brain MRI has shown absent signs of recurrence or tumor proliferation in the occipital bone and surrounding tissue [Figure 6].

DISCUSSION

GCTB is a rare entity in the skull, particularly in the occipital area. It commonly affects adults, but cases in children and even newborns have also been reported. According to a systematic review of cases originating in the skull, the gender distribution seems equal. However, some series have reported slight female or male predominance. In our review of reported cases in the occipital region, most patients were female adults; interestingly, the youngest patient was a 10-day male newborn [Table 1]. GCTB has also been reported in patients with neurofibromatosis, aneurysmal bone cysts, and Paget’s disease; however, there is no clear association, and risk factors remain unknown.

GCTB is considered a benign pathology, yet it can be aggressive when invades the surrounding tissue. Although infrequent, it may also present as a malignant variant. Besides, metastases can occur to the lungs, which usually course asymptomatic and associated with good treatment response.
The clinical presentation of GCTB in the occipital area is usually described as a tender and swollen lesion accompanied by headache, neck pain, vomiting or swelling of the affected area, and, less commonly, seizures. Furthermore, depending on the tumor extension into the neighboring area, it might cause lower cranial nerve deficits.

**Differential diagnosis**

The differential diagnosis of GCTB includes giant cell reparative granuloma, Paget's disease of the bone, aneurysmal cyst bone, chondroblastoma, chondromyxoid fibroma, nonossifying fibroma, fibrous dysplasia, pigmented villonodular synovitis, foreign body reactions, and brown tumors from hyperparathyroidism. These pathologies might be differentiated based on clinical history, laboratory tests, and imaging characteristics; nevertheless, a histopathological diagnosis is required. Although not pathognomonic, the common finding in a bone biopsy includes multiple multinucleated giant cells accompanied by ovoid-/spindle-shaped stromal cells. In addition, GTCB can be characterized...
through molecular and immunohistochemical markers, but their utility for screening and diagnosis has not been extensively proved.\textsuperscript{[12,24]} The tumor may exhibit high expression of the receptor activator of nuclear factor-kappa B ligand (RANKL), antigen Ki-67, CD68, vimentin, and lysozyme.\textsuperscript{[12,32,44,51]}

Imaging assessment modalities include computed tomography (CT) and magnetic resonance imaging (MRI). CT scan evaluates better periosteal reaction, pathologic fractures, and absence of matrix mineralization.\textsuperscript{[39]} On the contrary, MRI provides better delineation of the tumor extension through the enhanced resolution acquired with contrast in different sequences.\textsuperscript{[12,32]}

**Treatment**

GTR has been considered the main modality of treatment and warrants careful preoperative planning to provide the maximal extent of resection.\textsuperscript{[22,46,51]} When GTR is not possible due to a risk of damaging vital structures or further impairment of the neurological function, subtotal resection (STR), radiotherapy (RT), chemotherapy (e.g., Adriamycin, cisplatin, and doxorubicin), doxycycline sclerotherapy, denosumab, and bisphosphonates have been proposed as alternatives.\textsuperscript{[32]} In our review of cases, the majority of patients that underwent either GTR or STR + RT did not present tumor recurrence during the follow-up.

GTR and RT are favorable factors for progression-free survival of intracranial GCTB.\textsuperscript{[29,51]} Weng et al. recommended postoperative RT to patients with malignant pathology and Ki-67 index ≥10% regardless of the resection extent, residual tumors regardless of the Ki-67 index, and recurrent GCTB.\textsuperscript{[51]} The radiation dose is variable in the literature; some authors reported reasonable control with 35Gy, >40 Gy, or ≥45Gy.\textsuperscript{[10,38,53]} However, controversy still exists regarding the potential role of RT in the malignant sarcomatous transformation and the risk of recurrence.\textsuperscript{[10,20]}

Denosumab, a monoclonal antibody, decreases osseous destruction by inhibiting RANKL-expressing cells.\textsuperscript{[14]} It has been used as a neoadjuvant agent to decrease the tumor volume before surgical resection;\textsuperscript{[14,40]} however, denosumab might obscure the histological features of GCTB and mislead the pathological diagnosis as a result.\textsuperscript{[14]} On the other hand, Kajiwara et al. exemplified the use of denosumab as an adjuvant therapy to remove the remaining tumor when GTR was not achieved, which resulted in no recurrence of the tumor during a 5-year follow-up.\textsuperscript{[22]}

Doxycycline sclerotherapy, Adriamycin, and other chemotherapeutic agents have also shown to be effective when surgical resection is not possible, although in isolated cases.\textsuperscript{[32]} Töret et al. reported the use of cisplatin and doxorubicin in a 10-day newborn with GCTB of the occipital bone, which had compromised vascular structures.\textsuperscript{[47]}

The treatment effectively reduced the tumor size, and the lesion did not recur at a 60-month follow-up. However, the recommendation for using chemotherapy in GCTB of the skull is not well-established and has not reached a consensus. Zoledronic acid, a bisphosphonate agent, has been used less commonly in the skull compared to cases located in long bones.\textsuperscript{[16,56]} Its anti-osteoclastic activity might constitute a helpful tool in controlling local recurrence, but widespread clinical use has not been recommended.

As a result of the unpredictable tumor recurrence even after surgical and nonsurgical modalities of treatment, patients must undergo close surveillance with follow-up MRIs every 3–6 months for the first 5 years, for example.\textsuperscript{[51]}

**CONCLUSION**

GCTB rarely originates in the skull, being the occipital bone the most infrequent site of presentation. The gender distribution of this tumor in the skull is equal among adults; however, in the occipital area, females are more commonly affected. Besides, risk factors are still unknown and merit further investigation. A thorough clinical history, brain imaging, and histopathological analysis are essential for the diagnosis.

When feasible, total surgical resection effectively reduces the risk of recurrence. Nonetheless, radiation and adjuvant therapies have been employed when GTR could not be achieved. Ultimately, a close follow-up with brain MRIs is advised to control recurrence and further destruction of neighboring structures.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Arseni C, Horvath L, Maretsis M, Nicolae C. Giant cell tumors of the calvaria. J Neurosurg 1975;42:535–40.
2. Baena-Ocampo LD, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R. Epidemiology of bone tumors in Mexico City: Retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol 2009;13:16–21.
3. Bardakhchyan S, Kager L, Danielyan S, Avagyan A, Karamyan N, Vardevanyan H, et al. Denosumab treatment...
for progressive skull base giant cell tumor of bone in a 14 year old female a case report and literature review. Ital J Pediatr 2017;43:32.
4. Bertoni F, Unni KK, Beabout JW, Ebersold MJ. Giant cell tumor of the skull. Cancer 1992;70:1124-32.
5. Chan J, Gannon FH, Thompson LD. Malignant giant cell tumor of the sphenoid. Ann Diagn Pathol 2003;7:100-5.
6. Chatterjee D, Gupta K, Singla N, Kapoor A. Sphenoid bone: A rare site for giant cell tumor case report with literature review. Clin Neuropathol 2016;35:385-8.
7. Chugh A, Mohapatra A, Punia P, Gotecha SS, Choudhury P. Giant cell tumour of the occipital bone in a 13-year-old male. J Ayub Med Coll Abbottabad 2022;34:378-80.
8. Dai WY, Tian C, Liu L. Case reports of a giant cell reparative granuloma and a giant cell tumor on temporal bone. Chin Med J (Engl) 2018;131:2254-6.
9. Elder JB, Berry C, Gonzalez-Gomez I, Kreger MD, McComb JG. Giant cell tumor of the skull in pediatric patients. Report of two cases. J Neurosurg 2007;107:69-74.
10. Feigenberg SJ, Marcus Jr., RB, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 2003;411:207-16.
11. Feng Z, Wang C, Li B, Cheng A, Mao M, Han Z. Surgical management of giant cell tumor involving the lateral skull base. J Craniocac Surg 2019;30:1794-7.
12. Freeman JL, Oushy S, Schowinsky J, Sillau S, Youssef AS. Invasive giant cell tumor of the lateral skull base: A systematic review, meta-analysis, and case illustration. World Neurosurg 2016;96:47-57.
13. Giffin ME, Love JG. Giant-cell tumor of occipital bone with increased intracranial pressure: Report of a case. Proc Staff Meet Mayo Clin 1945;20:284-7.
14. Gilani A, Kleinschmidt-DeMasters BK. Denosumab therapy obscures histological features of giant cell tumor of bone. J Neuropathol Exp Neurol 2019;78:1171-3.
15. Gupta RK, Batra VV, Pahwa S, Bodeliwala S, Jagetia A, Singh D, et al. Skull-based giant cell tumor with atypical location highlighting the importance of intraoperative cytological examination: Report of four cases. Neurol India 2018;66:1507-9.
16. Harris AE, Beckner ME, Barnes L, Kassam A, Horowitz M. Giant cell tumor of the skull: A case report and review of the literature. Surg Neurol 2004;61:274-7.
17. Henderson BT, Whitwell H. Giant cell tumor of the skull: Case report. Neurosurgery 1988;23:120-2.
18. Huh A, Villelli N, Martinez D, Ting J, Birhiray R, Payner TD, et al. Denosumab treatment for a residual giant cell tumor of the clivus: A case report and review of the literature. World Neurosurg 2018;118:98-101.
19. Jadidi S, D’Abramo A, Barkley JF, Abusuwwa RF. Giant cell tumor of the frontal bone: A case report and literature review. Cureus 2018;10:e3353.
20. Jin SW, Sim KB, Kim SD. Development and growth of the normal cranial vault: An embryologic review. J Korean Neurosurg Soc 2016;59:192-6.
21. Kadiapaooglu C, Wahba A, Bhattacharjee MB, Cuglievan B, Fletcher SA. Hemorrhagic giant cell tumor of the occipital skull base: A case report and literature review. Cureus 2021;13:e13832.
22. Kajiwara Y, Takechi A, Watanabe Y, Miyoshi H, Shiraishi T. CS-01 giant cell tumor in the skull base bone treated with anti-rankl inhibitor. Neurooncol Adv 2019;1 Suppl 2:i38.
23. Kalani A, Lovett M, Stewart L, Popovic S, Panju A. A remote metastatic giant cell tumour to the skull. JRSM Open 2017;8:2054270417702567.
24. Karamanakos PN, Jaaskelainen JE, Alafuzoff I, Pirinen E, Vanninen R, Silvennoinen S, et al. Malignant giant cell tumor in the posterior fossa of a neonate. J Neurosurg Pediatr 2010;5:277-82.
25. Kaya I, Benzer M, Turhal G, Sercan G, Bilgen C, Kirazli T. Giant cell tumor of the temporal bone and skull base: A case report. J Int Adv Otol 2018;14:151-4.
26. Kubat R. Unusual presence of osteoclastoma in the occipital bone in children. Acta Chir Orthop Traumatol Cech 1961;28:246-7.
27. Larsson SE, Lorentzon R, Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish cancer registry for the years 1958 through 1968. J Bone Joint Surg 1975;57:167-73.
28. Lu ZH, Yao ZW. Giant cell tumour of the posterior cranial fossa: A case report. Br J Radiol 2011;84:208-11.
29. Modkovski R, Elliott R, Rubin B, Zagzag D, Jafar J, Mikolajenko I. Giant cell tumor of the occipital bone and secondary aneurysmal bone cyst: case report and review of literature. Intern J Neurosurg 2009:7.
30. Motomochi M, Handa Y, Makita Y, Hashi K. Giant cell tumor of the skull. Surg Neurol 1985;23:25-30.
31. Moyes PD, Bratty PJ, Dolman CL. Osteoclastoma of the jugular foramen. Case report. J Neurosurg 1970;32:255-7.
32. Murphey MD, Nomikos GC, Fleming DJ, Gannon FH, Temple HT, Kransdorf MJ. From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: Radiologic-pathologic correlation. Radiographics 2001;21:1283-309.
33. Opitz H, Petersen D, Heiss E, Duffner F, Meyermann R. Giant cell tumor of the occipital bone in a case of von Recklinghausen neurofibromatosis. Clin Neuropathol 1996;15:226-30.
34. Osaka S, Sugita H, Osaka E, Yoshida Y, Ryu J, Hemmi A, et al. Clinical and immunohistochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: Case series. J Orthop Surg (Hong Kong) 2004;12:55-62.
35. Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: A review of the literature. Technol Cancer Res Treat 2019;18:1533033819840000.
36. Patibandla MR, Thotakura AK, Rao MN, Addagada GC, Nukavarapu MC, Panigrahi MK, et al. Clival giant cell tumor a rare case report and review of literature with respect to current line of management. Asian J Neurosurg 2017;12:78-81.
37. Pousti BD, Andera L, Haugen TW. Sphenoid sinus giant cell tumor: A case report and literature review. ORL J Otorhinolaryngol Relat Spec 2020;82:168-74.
38. Prasad SC, Piccirillo E, Nuseir A, Sequino G, De Donato G, Pratesi CS-01 giant cell tumor in the skull base bone treated with anti-rankl inhibitor. Neurooncol Adv 2019;1 Suppl 2:i38.
39. Seider MJ, Rich TA, Ayala AG, Murray JA. Giant cell tumors of bone: Treatment with radiation therapy. Radiology 1986;161:537-40.
40. Sekar A, Rudrappa S, Gopal S, Ghosal N, Gupta V, Ts L. Preoperative cytoreduction of clival giant cell tumor: An effective replication of the systemic modality in the skull base. World Neurosurg 2018;119:97-102.
41. Sepulveda I, Alzerrerca J, Villalobos P, Ulloa JP. Giant cell tumor of the temporal bone with skull base and middle ear extension. J Med Cases 2021;12:149-51.
42. Shah SR, Keshri A, Behari S, Patadia S, Kumari N. Giant cell granuloma of the anterior skull base: Need for early, maximal surgical excision: A short series of 3 cases with review of literature. Indian J Otolaryngol Head Neck Surg 2015;67:347-52.
43. Sharma V, Newton G. Osteoclastoma of occipital bone. Yonsei Med J 1991;32:169-71.
44. Stagner AM, Sajed DP, Nielsen GP, Ebb DH, Faquin WC, Chebib I, et al. Giant cell lesions of the maxillofacial skeleton express RANKL by RNA in situ hybridization regardless of histologic pattern. Am J Surg Pathol 2019;43:819-26.
45. Sung J, Jin K, Jae J, Young K, Hook S. A case report of giant cell tumor of the occipital bone. Arch Craniofac Surg 2010;11:103-6.
46. Tamura R, Miwa T, Shimizu K, Mizutani K, Tomita H, Yamane N, et al. Giant cell tumor of the skull: Review of the literature. J Neurolog Surg A Cent Eur Neurosurg 2016;77:239-46.
47. Töret E, Demirağ B, Calakvur Ş, Doğanayşargil B, Turhan T. Case report a newborn with giant cell tumor of the occipital bone: Case report address for correspondence. J Pediatr Res 2019;6:256-64.
48. Troell A. Two cases of giant cell tumor in bone observed 3½ and 18 years. Acta Chir Scand 1930;67:906-13.
49. Uslu GH, Canyilmaz E, Yöney A, Aydin S, Sahbaz A, Sarı A. Giant cell tumor of the occipital bone: A case report and review of the literature. Oncol Lett 2014;8:151-4.
50. Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: Are there associated factors and best treatment modalities? Clin Orthop Relat Res 2010;468:827-33.
51. Weng JC, Li D, Wang L, Wu Z, Wang JM, Li GL, et al. Surgical management and long-term outcomes of intracranial giant cell tumors: A single-institution experience with a systematic review. J Neurosurg 2018;131:695-705.
52. Wong MN, Nicol K, Murakami JW. Image-guided percutaneous management of skull and spine giant cell tumors: Case report of 2 challenging cases successfully treated with doxycycline sclerotherapy. World Neurosurg X 2020;5:100061.
53. Yaprak Bayrak B, Özcan E, Vural Ç, Emengen A, Çabuk B, Ceylan S. A single-center experience with giant cell tumors of sphenoid bone and clivus. Tumori 2021;107:NP94-100.
54. Young-Min K, Yong-Sook P, Se-Hoon K, Jong-Hee C, Yong-Gou P. Giant cell tumor of the occipital bone. J Korean Brain Tumor Soc 2004;3:152-5.
55. Zhang Z, Xu J, Yao Y, Chu S, Cheng H, Chen D, et al. Giant cell tumors of the skull: A series of 18 cases and review of the literature. J Neurooncol 2013;115:437-44.
56. Zvolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, et al. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am 2010;92:162-8.

How to cite this article: Bocanegra-Becerra JE, Showing MG, Tanta LA. Surgical management of giant cell tumor invading the occipital bone: A case report and literature review. Surg Neurol Int 2022;13:351.